Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
- PMID: 20967171
- PMCID: PMC2957495
- DOI: 10.2450/2010.0072-10
Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
Comment in
-
Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.Blood Transfus. 2010 Oct;8(4):292-6. doi: 10.2450/2010.0067-10. Blood Transfus. 2010. PMID: 20967172 Free PMC article. No abstract available.
References
-
- Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia. 2008;14(Suppl 3):10–8. - PubMed
-
- Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 1999;39:1160–8. - PubMed
-
- Tagliaferri A, Rivolta GF, Iorio A, et al. Italian Association of Hemophilia Centers Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia. 2010;16:437–46. - PubMed
-
- Astermark J, Santagostino E, Keith Hoots W. Clinical issues in inhibitors. Haemophilia. 2010;16(Suppl 5):54–60. - PubMed
-
- Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia. 2009;5:263–5. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical